The American Society for Radiation Oncology (ASTRO) has released evidence-based guidelines supporting the use of hypofractionated (HF) whole breast irradiation (WBI) for certain patients with early-stage breast cancer, based on the findings of a study published in the August edition of the International Journal of Radiation, Oncology, Biology and Physics.
The American Society for Radiation Oncology (ASTRO) has named N. Reed Dunnick, MD, as its 2010 honorary member, which is the highest honor the society bestows upon distinguished cancer researchers and leaders in disciplines other than radiation oncology, radiation physics or radiobiology.
The American Society for Radiation Oncology (ASTRO) research evaluation committee has named the recipients of the junior faculty career research training award and the residents/fellows in Radiation Oncology Research Seed Grant Award.
According to a recently released report by the American Society for Radiation Oncology (ASTRO), stereotactic body radiotherapy (SBRT) in the treatment of lung cancer can be a reasonable alternative to surgery in certain cases of the disease.
American Society for Radiology Oncology (ASTRO) President Anthony Zietman, MD, of Massachusetts General Hospital and Harvard University in Boston, said that radiation treatment should be employed as opposed to the watchful waiting method, as doctors currently have little way to tell if prostate cancer will progress or remain somewhat asymptomatic.
The Council of Medical Specialty Societies (CMSS) has released the CMSS Code for Interactions with Companies, which provides detailed guidance to medical specialty societies on appropriate interactions with for-profit companies in the healthcare sector.
In a statement responding to the FDA’s letter to radiation equipment manufacturers announcing it was taking steps to strengthen the approval process for radiotherapy devices, the American Society for Radiation Oncology Chairman Tim Williams said the organization “support[s] the retention of the 510(k) clearance process, but urge[s] that appropriate safeguards be implemented to ensure that new technology is safe and effective."
The American Society for Radiation Oncology (ASTRO) and the FDA have launched radiation safety initiatives to enhance the safety of medical radiation and to reduce unnecessary exposure in patients, according to an article published in the April 7 issue of Journal of the American Medical Association.
Highly contoured intensity-modulated radiotherapy (IMRT) may be a successful strategy for reducing morbidity in prostate cancer treatment, as patients involved were found to have less radiotherapy related morbidity than their counterparts treated with conventional target volume margins, based on study findings published online Feb. 16 in Urology.
Through a collaborative effort by the American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR), practice guidelines for image guided radiation therapy and stereotactic body radiation therapy have been created and released to assist practitioners in providing appropriate radiologic care for patients.
In acknowledgment of recent media reports regarding serious errors in the delivery of radiation therapy, the American Society for Radiation Oncology (ASTRO) last week released a six-point patient protection plan that seeks to improve safety and quality, while reducing the chance of medical errors.
The American Society for Radiation Oncology (ASTRO) has announced that nine radiation oncology equipment manufacturers passed at least one portion of interoperability at its third Integrating the Healthcare Enterprise–Radiation Oncology (IHE-RO) Connectathon.
Post-lumpectomy radiation treatment for early-stage breast cancer can be safely reduced to four weeks by delivering a higher daily dose, according to the five-year results of a phase II study presented Wednesday at the 2009 American Society for Radiation Oncology (ASTRO) in Chicago.
Radiation therapy and chemotherapy given before prostatectomy is safe and may have the potential to reduce cancer recurrence and improve patient survival, based on study findings presented this week at the 2009 American Society of Radiology Oncology (ASTRO) conference in Chicago.
An abridged, intensified radiation course proved to be as effective as the standard five- to seven-week treatment in early-stage breast cancer patients, based on results of a study presented Wednesday at the 2009 American Society for Radiation Oncology (ASTRO) conference in Chicago.
Simultaneous use of chemotherapy and high-dose radiotherapy has produced encouraging results in the treatment of limited-stage small-cell lung cancer, according to a phase II study presented Tuesday at the 2009 American Society for Radiation Oncology (ASTRO) meeting in Chicago.
A two-and-a-half week shorter radiation treatment for prostate cancer is as effective as a traditional seven-week treatment, according to results of a study presented Thursday at the 2009 American Society for Radiation Oncology (ASTRO) conference in Chicago.
Hypofractionated radiation treatment is more effective than conventional radiation therapy for preventing cancer growth in high-risk prostate cancer patients, according to a study presented at the 2009 American Society for Radiation Oncology (ASTRO) meeting in Chicago.
Breast cancer patients who receive radiation treatment after a mastectomy do not have a greater life expectancy than those who do not receive treatments, according to the results of a 10-year randomized trial presented Monday at the American Society for Radiation Oncology (ASTRO) conference in Chicago.
Instead of the 19 percent of proposed cuts to radiation oncology, the Centers for Medicare & Medicaid Services (CMS) has decided to implement a 5 percent reduction, phased in over a four-year period in its 2010 Medicare Physician Fee Schedule. As a result, CMS reimbursements for radiation oncology treatments will be reduced by 1 percent in 2010.
|